BI-RADS

From WikiMD's WELLNESSPEDIA

BI-RADS (Breast Imaging-Reporting and Data System) is a standardized system developed by the American College of Radiology (ACR) to categorize and report findings in breast imaging. The system is designed to improve communication between radiologists and referring physicians, ensure consistent reporting, and facilitate research and data collection.

History[edit]

The BI-RADS system was first introduced in 1993 and has undergone several revisions to incorporate advances in breast imaging technology and clinical practice. The most recent edition, BI-RADS 5th Edition, was published in 2013.


BI-RADS categorizes breast imaging findings into seven categories, each with specific management recommendations:

  • BI-RADS 0: Incomplete
 - Additional imaging evaluation and/or comparison to prior mammograms is needed.
  • BI-RADS 1: Negative
 - No significant findings; routine screening recommended.
  • BI-RADS 2: Benign
 - Non-cancerous findings; routine screening recommended.
  • BI-RADS 3: Probably Benign
 - Findings have a high probability of being benign; short-interval follow-up suggested.
  • BI-RADS 4: Suspicious
 - Findings are suspicious for malignancy; biopsy should be considered. This category is further divided into:
   - 4A: Low suspicion for malignancy
   - 4B: Moderate suspicion for malignancy
   - 4C: High suspicion for malignancy
  • BI-RADS 5: Highly Suggestive of Malignancy
 - Findings have a high probability of being cancer; appropriate action should be taken.
  • BI-RADS 6: Known Biopsy-Proven Malignancy
 - Lesions confirmed to be malignant by biopsy; appropriate action should be taken.

Imaging Modalities[edit]

BI-RADS is used across various breast imaging modalities, including:

Importance[edit]

The BI-RADS system plays a crucial role in the early detection and management of breast cancer. It standardizes reporting, which helps in the accurate assessment of breast lesions and ensures that patients receive appropriate follow-up and treatment.

Related Pages[edit]

References[edit]


External Links[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.